Plasma glucagon in insulinoma

Ohneda, Akira; Matsuda, Kiyoshi; Horigome, Ken; Ishii, Soh; Yanbe, Akira; Maruhama, Yoshisuke

doi:10.1007/bf02580970

Cited by 2 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a few reports dealing with plasma glucagon in insulinoma. 1 Another explanation is an increased secretion of glucagon from the islet cell tumor. Similarly, an increase in plasma glucagon was reported in patients with malignant islet cell tumor.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, an increase in plasma glucagon was reported in patients with malignant islet cell tumor. 17 Furthermore, recent studies indicate that additional hormones, such as gastrin, somatostatin, and pancreatic polypeptide, were proved in insulinoma tumors by means of immunoassay or morphologic investigation. 1 Such an elevated plasma glucagon in islet cell tumor could be ac- counted for as follows: first, frequent hypoglycemic attacks may induce an exaggerated glucagon secretion from the A cells of the uninvolved pancreas.…”

Section: Discussionmentioning

confidence: 99%

“…1 However, the origin of the elevated response of plasma glucagon has not been fully explained. 1 However, the origin of the elevated response of plasma glucagon has not been fully explained.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A Malignant Insulinoma Transformed into a Glucagonoma Syndrome

et al. 1979

Self Cite

View full text Add to dashboard Cite

AKIRA OHNEDA, MASAO OTSUKI, HIROSHI FUJIYA, NOBUHISA YAGINUMA, TAKESHI KOKUBO, AND HARUO OHTANI SUMMARY A 55-yr-old man was admitted to the Hospital of Tohoku University in 1970, when physical examination and laboratory findings revealed malignant insulinoma with metastases to the liver. Streptozotocin treatment, totaling 79.5 g for 1 yr, improved his clinical symptoms. After discharge he was well until 1977, when he complained of palpitation and dyspnea, and he was hospitalized in September 1977 because of anorexia and a loss of body weight. Laboratory findings revealed anemia, with a decrease both in serum albumin and iron. His fasting blood glucose was 74 mg/dl and plasma insulin (IRI) 25 ^U/ml. His plasma IRI increased slightly after the stimuli of glucose, arginine, and glucagon. In contrast, his plasma glucagon (IRG) increased at fasting (3372 pg/ml) and became markedly elevated after arginine or glucose was administered. After his final admission, diazoxide improved his symptoms temporarily; streptozotocin could not be administered because of dyspnea and palpitation. On 24 January 1978, he fell suddenly into a coma and 2 days later he died. An autopsy revealed a large pancreatic tumor and metastases to the liver. Measurement of hormones from the tissues revealed a smaller amount of IRI in the pancreatic tumor and liver metastases compared with that in the uninvolved pancreas. In contrast, IRG contents had increased in the pancreatic tumor and hepatic metastases. In addition to the insulin cells, numerous cells with glucagon and somatostatin were observed in morphologic examinations. This indicated a mixed endocrine pancreatic tumor exhibiting typical symptoms of insulinoma initially and a glucagonoma syndrome later. DIABETES 28:962-969, November 1979.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Malignant Insulinoma Transformed into a Glucagonoma Syndrome

et al. 1979

Self Cite

View full text Add to dashboard Cite

show abstract

Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases

Blum

Rusecki

Doron

et al. 1983

J Endocrinol Invest

View full text Add to dashboard Cite

Two patients suffering from benign and one patient suffering from malignant insulinoma experienced frequent incapacitating hypoglycemic attacks which did not respond to treatment with streptozotocin, diazoxide and/or diphenylhydantoin. Dl-propranolol, in dosages ranging from 30-240 mg/day, successfully abolished the symptoms of hypoglycemia, prevented recurrent hypoglycemic attacks, and normalized blood glucose levels concomitant with a reduction in pulse rate to 60/min. The main mechanism of the drug's effect seems to be the suppression of insulin release. However, other mechanisms may be involved such as increased peripheral insulin resistance. No side effects of treatment with dl-propranolol were noted. In patients suffering from insulinoma who are refractory to other forms of treatment, and for those who need symptomatic relief before surgery, dl-propranolol may play an important therapeutic role.

show abstract

Plasma glucagon in insulinoma

Cited by 2 publications

References 22 publications

A Malignant Insulinoma Transformed into a Glucagonoma Syndrome

A Malignant Insulinoma Transformed into a Glucagonoma Syndrome

Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases

Contact Info

Product

Resources

About